Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
311 Leser
Artikel bewerten:
(1)

Vituity: Jovive Launches Two New Outpatient Wound Care Clinics in Southern California

Finanznachrichten News

Expanding Access to Specialized Wound Care

EMERYVILLE, CA / ACCESSWIRE / January 8, 2024 / Jovive, a provider of patient-centric outpatient healthcare services that is owned and operated by Vituity, is pleased to announce the grand opening of Jovive Wound Care outpatient clinics in Mission Viejo and Loma Linda, CA. These two specialized facilities are dedicated to delivering comprehensive wound care services in an outpatient setting to help enhance patient outcomes and improve overall quality of life.

Providing wound care in an outpatient setting has been found to minimize the risk of infections and promote faster wound healing by providing a controlled environment where providers can monitor and manage wounds while keeping patients out of the hospital setting. Jovive Wound Care clinics also help reduce the total cost of care by eliminating the need for prolonged hospital stays, reducing the overall burden on healthcare resources, and making it easier for patients to access timely and appropriate care.

"The Southern California communities of Mission Viejo and Loma Linda have been in need of wound care locally, with some residents traveling up to an hour away to receive treatments which could involve weekly appointments," said Evan Houck, DO, Medical Director, Jovive Wound Care, Loma Linda. "Our physician leaders and innovators identified the need of those communities and are excited to launch two outpatient wound care clinics to serve these areas. We look forward to actively engaging in these communities via outreach programs throughout the year."

Jovive is committed to simplifying wound care from start to recovery by offering seamless care coordination and support to communities. From coordinating transportation to providing post-visit follow-ups, Jovive guides patients at every step while working to alleviate gaps in care and raise awareness about wound care and prevention. The two new outpatient wound care clinics developed a physician-designed technology platform to help document, track, and enhance performance.

"By integrating intensive training, innovative technology, and proven protocols, we enhance healing and remission rates, minimize infections and complications, and achieve enduring results," said Bill Khoury, MD, Medical Director, Jovive Wound Care, Mission Viejo. "In addition, outpatient wound care is often more cost-effective than inpatient care. As an outpatient practice, Jovive Wound Care eliminates facility fees and is in a patient's community, reducing travel and making it easier for patients to complete treatment without relapse."

Patients can learn more about the Mission Viejo clinic (26732 Crown Valley Pky, Suite 585, Mission Viejo, CA 92691; 909-435-4852) or the Loma Linda clinic (11340 Mountain View Ave, Suite B, Loma Linda, CA 92354; 949-850-9964) at JoviveWoundCare.com. Both clinics are open Monday-Friday from 8 a.m. to 5 p.m. Pacific Standard Time.

About Jovive, part of?Vituity

Jovive is owned and operated by Vituity, a national physician partnership with a history of healthcare quality and innovation. As a 100% physician-led and -owned multispecialty partnership with a nationwide footprint, nearly 5,000 Vituity clinicians care for more than 8 million patients across 450 practice locations.?

Contact Information

Jacob Voss
Associate Director, Media and Engagement
jvoss@realchemistry.com
(651) 964-8756

SOURCE: Jovive Health

.

View the original press release on newswire.com.

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.